Amgen culls early-stage obesity candidate, makes pipeline updates

Phase 1negativeAMG-513Negative

AI Analysis

Summary

Amgen is discontinuing AMG-513, an early-stage Phase 1 obesity candidate, with limited details provided about the program or reasons for the termination.

Clinical Trial Data

Phase

Outcome Details

early-stage obesity candidate discontinued

Importance:3/10

Sentiment:

-0.60

pipeline updatePhase 1 discontinuationobesityprogram termination

Related Companies

$AMGN

Read the original article

Published by Endpoints News on August 4, 2026 8:01 PM

Read Original